The information provided in this web site is intended to educate the reader about certain medical conditions and certain possible treatments. It is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. If you believe you, suffer from the conditions described herein, please see your health care provider. Do not attempt to treat yourself or anyone else without proper medical supervision.
Read the Full Disclaimer
The Consortium
The MitoTarget consortium has extensive expertise in neurodegenerative diseases:
The aim of running both basic research on mitochondrial dysfunctions in neurodegenerative diseases alongside the clinical validation of mitochondrial targeted treatments has required a consortium bringing together 17 partners from 5 European countries (France, Germany, United Kingdom, Spain and Belgium).
Each individual member of the consortium contributes experience or knowledge of neurodegenerative diseases and / or specifically in the area of mitochondrial dysfunction.
The members are divided into two groups, with Trophos as co-ordinator:
Group 1
A clinical research group of 15 clinical investigators. These investigators are already recognised as a world leading group in ALS clinical trials. The group has already participated in the clinical development of riluzole (Sanofi-Aventis), the only approved drug for ALS.
This group brings to the MitoTarget project two essential ingredients:
- knowledge and experience of well known clinical models of neurodegenerative diseases which will provide the basis for validation of both the findings as well as data generated by the Research & Technical Development part of the project
- Experience of running a significant clinical trial (up to 476 patients); including protocol writing, the establishment of clinical methodology, enrolment of patients, and expertise in clinical trial management involving patients with progressive paralysis and who may decline rapidly
Group 2
5 basic research partners that are among the best European specialists of mitochondrial dysfunction and neurodegenerative diseases. They will enable the exploration of the multiple mechanisms involved in, or resulting from, mitochondrial dysfunction. This exploration will, in part, involve a new class of mitochondrial targeted compounds developed by Trophos, in a wide range of neurodegenerative conditions through the use of relevant in vitro and in vivo models of AD, HD, HSP and ALS.
Co-Ordinator
Trophos was founded in order to discover and develop new drugs to treat both orphan neurodegenerative diseases and more prevalent disorders. After ten years of operation, the company has entered two NCEs (new chemical entities) into clinical development. Regarding clinical trials, its lead compound, TRO19622 (olesoxime) has completed all preclinical and phase I prerequisites to support initiating a phase II/III trial in any indication, or disease.
The link between these two groups is TRO19622, olesoxime, one of a new class of mitochondrial targeted compounds. Trophos, the company at the origin of this discovery, aims to establish this compound as the first of a new class of therapeutic agents that will bring significant therapeutic benefit to patients suffering from devastating neurological diseases.
